scispace - formally typeset
J

James Lee

Researcher at Daiichi Sankyo

Publications -  33
Citations -  1598

James Lee is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Amlodipine & Olmesartan. The author has an hindex of 17, co-authored 33 publications receiving 1325 citations. Previous affiliations of James Lee include University of Washington.

Papers
More filters
Journal ArticleDOI

Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017

Rafael Lozano, +1316 more
- 10 Nov 2018 - 
TL;DR: A global attainment analysis of the feasibility of attaining SDG targets on the basis of past trends and a estimates of health-related SDG index values in countries assessed at the subnational level varied substantially, particularly in China and India, although scores in Japan and the UK were more homogeneous.
Journal ArticleDOI

Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

Christopher J L Murray, +1095 more
- 10 Nov 2018 - 
TL;DR: This work estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods and used the cohort-component method of population projection, with inputs of fertility, mortality, population, and migration data.
Journal ArticleDOI

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

TL;DR: The combination of OM and AML was effective and well tolerated in this adult population with hypertension and was associated with dose-dependent reductions in SeDBP that were significantly greater than the reductions with the corresponding component monotherapies.
Journal ArticleDOI

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

TL;DR: After 90 days, the reduction in bleeding risk with edoxaban versus warfarin was similarly beneficial across genotypes, and treatment with Edoxaban reduced bleeding more so in sensitive and highly sensitive responders than in normal responders.
Journal ArticleDOI

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.

TL;DR: Triple combination treatment with OM, amlodipine besylate, and hydrochlorothiazide had a clinically significant benefit compared with dual combinations of the individual components in patients with moderate to severe hypertension, a multicenter, randomized, doubleblind, parallel-group study.